These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30029821)

  • 1. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto J;
    Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto JWF
    Eur Urol; 2019 Feb; 75(2):e29-e30. PubMed ID: 30471881
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO).
    Necchi A; Messina A; Briganti A
    Eur Urol; 2018 Nov; 74(5):e107-e108. PubMed ID: 30318068
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Teoh JYC; Herrmann TRW; Babjuk M
    Eur Urol; 2019 Feb; 75(2):e27-e28. PubMed ID: 30262343
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Sungmin Woo, Valeria Panebianco, Yoshifumi Narumi, Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020;3:306-315.
    Glykas I; Fragkoulis C; Kapogiannis F; Ntoumas K
    Eur Urol Oncol; 2020 Aug; 3(4):555-556. PubMed ID: 32536572
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Stavrinides V; Giganti F; Emberton M; Moore CM
    Eur Urol; 2020 Oct; 78(4):e166. PubMed ID: 32712048
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Mottet N; Wiegel T;
    Eur Urol; 2020 Nov; 78(5):e193-e194. PubMed ID: 32838999
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti's Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. Eur Urol 2016;70:588-96.
    Freedland SJ; Den RB
    Eur Urol; 2016 Oct; 70(4):e110-e111. PubMed ID: 26992279
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567-72.
    Vickers AJ
    Eur Urol; 2021 Dec; 80(6):e149. PubMed ID: 34600778
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur Urol 2019;76:284-303: The choice of diagnostic test in prostate cancer is a balance of the risks and benefits: One size may not fit all.
    Kasivisvanathan V; Takwoingi Y; Emberton M; Moore CM
    Eur Urol; 2019 Nov; 76(5):e133-e134. PubMed ID: 31400949
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol 2023;6:508-15.
    D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
    Eur Urol Oncol; 2024 Jun; 7(3):639-640. PubMed ID: 37978025
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9.
    Del Giudice F; Catto JWF; Panebianco V
    Eur Urol; 2020 Apr; 77(4):e94-e95. PubMed ID: 32005552
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Marco Moschini, Francesco Montorsi, Giuseppe Rosiello, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Stamatios Katsimperis, Lazaros Tzelves, Zafer Tandogdu, et al. Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis. Eur Urol Focus 2023;9:920-9.
    Katsimperis S; Tzelves L; Tandogdu Z; Ta A; Geraghty R; Bellos T; Manolitsis I; Pyrgidis N; Schulz GB; Sridhar A; Shaw G; Kelly J; Skolarikos A
    Eur Urol Focus; 2024 May; ():. PubMed ID: 38749880
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.
    Soria F; Gontero P
    Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38278711
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Francesco Montorsi, Nicola Fossati, Carlo A. Bravi, Giorgio Gandaglia, Nazareno Suardi, and Alberto Briganti's Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537-44. Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion?
    Knipper S; Maurer T
    Eur Urol; 2021 May; 79(5):e134. PubMed ID: 33579574
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Gianluca Giannarini, Nazareno Suardi and Alberto Briganti's letter to the editor re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22 393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.11.018.
    Sooriakumaran P; Wiklund P; Roobol MJ; Steyerberg E; Sanchez-Salas R; Cathelineau X; Tewari AK
    Eur Urol; 2014 Jun; 65(6):e91-2. PubMed ID: 24447573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.